NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies

Reuters

2025/10/22

NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies

NanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577936256"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577936256\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577936256?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577936256","market":"nz","top_or_hot":-1,"title":"NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-22 20:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL8lDxP0:1","article_id":"2577936256","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577936256","pubTimestamp":1761137122,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.Disclaimer: This news brief was created by Public Technologies  using generative artifi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NNVC":"NanoViricides Inc.","BK4568":"美国抗疫概念"},"translate_title":"NanoViricides报告NV-387在临床前研究中对麻疹具有很强的抗病毒活性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Reports Strong Antiviral Activity for NV-387 Against Measles in Preclinical Studies\n    \n\nNanoViricides Inc. announced that its clinical lead drug, NV-387, has demonstrated strong antiviral activity against the Measles virus in both cell culture studies and a humanized animal model. The company reported that NV-387 treatment led to protection of lung tissue, an important outcome for patients with severe viral infections. According to NanoViricides, NV-387 has completed a Phase I clinical trial in healthy subjects, showing no reportable adverse events and was found to be safe and well tolerated. The company highlighted that NV-387 is a multi-purpose, broad-spectrum antiviral currently being developed for several respiratory viral infections, including RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, MPox, and Smallpox. Results from the studies have already been presented. NanoViricides is seeking additional funding to support further development of NV-387 as a treatment for Measles.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1090472) on October 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}